Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)

About Bellicum Pharmaceuticals (NASDAQ:BLCM)

Bellicum Pharmaceuticals logoBellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLCM
  • CUSIP: N/A
  • Web: www.bellicum.com
Capitalization:
  • Market Cap: $375.13 million
  • Outstanding Shares: 33,226,000
Average Prices:
  • 50 Day Moving Avg: $9.61
  • 200 Day Moving Avg: $11.71
  • 52 Week Range: $7.41 - $23.11
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.99
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $323,000.00
  • Price / Sales: 1,173.71
  • Book Value: $3.70 per share
  • Price / Book: 3.08
Profitability:
  • EBIDTA: ($79,180,000.00)
  • Net Margins: -17,957.31%
  • Return on Equity: -70.74%
  • Return on Assets: -53.29%
Debt:
  • Debt-to-Equity Ratio: 0.22%
  • Current Ratio: 8.34%
  • Quick Ratio: 8.34%
Misc:
  • Average Volume: 850,539 shs.
  • Beta: 1.23
  • Short Ratio: 9.65
 

Frequently Asked Questions for Bellicum Pharmaceuticals (NASDAQ:BLCM)

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its earnings results on Tuesday, August, 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period last year, the firm earned ($0.61) earnings per share. View Bellicum Pharmaceuticals' Earnings History.

When will Bellicum Pharmaceuticals make its next earnings announcement?

Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Bellicum Pharmaceuticals.

Where is Bellicum Pharmaceuticals' stock going? Where will Bellicum Pharmaceuticals' stock price be in 2017?

5 brokerages have issued 12-month price targets for Bellicum Pharmaceuticals' stock. Their forecasts range from $16.00 to $35.00. On average, they expect Bellicum Pharmaceuticals' stock price to reach $26.20 in the next year. View Analyst Ratings for Bellicum Pharmaceuticals.

What are analysts saying about Bellicum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. " (3/16/2017)
  • 2. Cantor Fitzgerald analysts commented, "Following Bellicum's 4Q16 earnings conference call, we are reiterating our Overweight rating and $32 price target. Bellicum provided several updates outlining its plans for 2017, including: 1) progress in its current BP-004 trial with BPX-501 in malignant and non-malignant pediatric transplant patients, 2) greater clarity from the FDA on the development path of BPX-501 in the U.S., and 3) updates on its expanding CAR and TCR oncology programs. Looking forward, we expect additional updated data at the European Hematology Association (EHA) meeting being held in June and an update on the finalized U.S. registration trial design in mid-2017." (3/14/2017)
  • 3. Jefferies Group LLC analysts commented, "BLCM presented long term data consistent with the ASH 2016 readout, demonstrating low rates of GvHD and relapse. One theme of the meeting we found interesting was the ongoing debate on whether T cells are necessary to prevent BMT complications and relapse. Further, conversations with docs highlighted the discordant strategies for GvHD prevention." (2/27/2017)

Who are some of Bellicum Pharmaceuticals' key competitors?

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the folowing people:

  • James Farrell Brown, Independent Chairman of the Board
  • Richard A. Fair, President, Chief Executive Officer, Director
  • David M. Spencer Ph.D., Founder, Chief Scientific Officer
  • Kevin M. Slawin M.D., Founder
  • Alan A. Musso CPA, Chief Financial Officer, Treasurer
  • Ken Moseley J.D., Senior Vice President, General Counsel, Corporate Secretary
  • James M. Daly, Independent Director
  • Stephen R. Davis, Independent Director
  • Reid M. Huber Ph.D., Independent Director
  • Frank B. McGuyer, Independent Director

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

Who owns Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.43%), JPMorgan Chase & Co. (7.45%), Vanguard Group Inc. (3.64%), State Street Corp (1.25%), Northern Trust Corp (1.03%) and Sphera Funds Management LTD. (0.76%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Annemarie Moseley, Bros Advisors Lp Baker, David M Spencer, Ken Moseley, Kevin M Slawin and Thomas J Farrell. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

Who sold Bellicum Pharmaceuticals stock? Who is selling Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., FMR LLC, Tudor Investment Corp ET AL, Mcdaniel Terry & Co., Fred Alger Management Inc. and Berson & Corrado Investment Advisors LLC. Company insiders that have sold Bellicum Pharmaceuticals stock in the last year include Alan A Musso, Alan K Smith, Annemarie Moseley, David M Spencer, Ken Moseley and Kevin M Slawin. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Who bought Bellicum Pharmaceuticals stock? Who is buying Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Vanguard Group Inc., Numeric Investors LLC, Goldman Sachs Group Inc., Northern Trust Corp, Virtu KCG Holdings LLC, State Street Corp and Sphera Funds Management LTD.. View Insider Buying and Selling for Bellicum Pharmaceuticals.

How do I buy Bellicum Pharmaceuticals stock?

Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bellicum Pharmaceuticals' stock price today?

One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $11.41.


MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bellicum Pharmaceuticals (NASDAQ:BLCM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.20 (129.62% upside)

Analysts' Ratings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Jefferies Group LLCReiterated RatingBuy$16.00LowView Rating Details
8/9/2017Raymond James Financial, Inc.Set Price TargetBuy$29.00 -> $18.00HighView Rating Details
6/27/2017Wells Fargo & CompanyReiterated RatingOutperform$31.00LowView Rating Details
6/26/2017Cantor FitzgeraldReiterated RatingOverweight$35.00LowView Rating Details
6/24/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$31.00LowView Rating Details
8/9/2016Piper Jaffray CompaniesReiterated RatingOverweight$25.00 -> $31.00N/AView Rating Details
8/9/2016Citigroup Inc.UpgradeNeutral -> Buy$24.00N/AView Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$20.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Earnings by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Earnings History by Quarter for Bellicum Pharmaceuticals (NASDAQ BLCM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.73)N/AView Earnings Details
8/8/2017Q2 2017($0.65)($0.74)$0.08 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.70)($0.80)$0.09 million$0.13 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.71)($0.74)$0.10 million$0.08 millionViewN/AView Earnings Details
11/9/2016Q3($0.63)($0.66)$0.09 million$0.11 millionViewN/AView Earnings Details
8/8/2016Q216($0.57)($0.61)$0.10 million$0.10 millionViewListenView Earnings Details
3/14/2016Q415($0.44)($0.63)$2.00 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.38)($0.51)$0.18 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q215($0.49)($0.40)$0.23 million$0.08 millionViewListenView Earnings Details
5/11/2015Q1($0.22)($0.30)$0.50 million$0.11 millionViewN/AView Earnings Details
3/11/2015Q4($11.79)($2.02)$0.60 million$0.02 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)
2017 EPS Consensus Estimate: ($2.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.72)($0.71)($0.72)
Q2 20172($0.67)($0.63)($0.65)
Q3 20172($0.76)($0.74)($0.75)
Q4 20172($0.79)($0.74)($0.77)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 55.73%
Insider Trades by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Insider Trades by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Alan K. SmithEVPSell437$11.85$5,178.45View SEC Filing  
7/13/2017Ken MoseleyVPSell13,823$12.26$169,469.98View SEC Filing  
7/10/2017David M. SpencerInsiderSell10,000$11.54$115,400.00View SEC Filing  
5/25/2017Alan A. MussoCFOSell6,311$12.24$77,246.64View SEC Filing  
3/24/2017Bros. Advisors Lp BakerMajor ShareholderBuy166,666$12.00$1,999,992.00View SEC Filing  
2/7/2017Kevin M SlawinDirectorSell30,000$12.54$376,200.00View SEC Filing  
12/15/2016Kevin M SlawinInsiderSell30,000$15.45$463,500.00View SEC Filing  
12/5/2016David M SpencerInsiderSell5,000$20.00$100,000.00View SEC Filing  
12/1/2016Annemarie MoseleyCOOSell25,000$17.54$438,500.00View SEC Filing  
11/28/2016Alan A. MussoCFOSell29,300$19.51$571,643.00View SEC Filing  
9/23/2016Ken MoseleyVPSell11,800$20.10$237,180.00View SEC Filing  
9/23/2016Kevin M SlawinInsiderSell23,416$20.12$471,129.92View SEC Filing  
9/20/2016David M SpencerInsiderSell2,500$20.01$50,025.00View SEC Filing  
9/20/2016Ken MoseleyVPSell2,200$20.01$44,022.00View SEC Filing  
8/15/2016Ken MoseleyVPSell1,000$20.00$20,000.00View SEC Filing  
8/15/2016Kevin M SlawinInsiderSell67,000$19.31$1,293,770.00View SEC Filing  
7/27/2016David M. SpencerInsiderSell10,000$15.00$150,000.00View SEC Filing  
7/18/2016Kevin M SlawinCTOSell2,719$13.99$38,038.81View SEC Filing  
7/15/2016Kevin M SlawinCTOSell22,281$13.72$305,695.32View SEC Filing  
6/2/2016Annemarie MoseleyCOOSell25,000$13.00$325,000.00View SEC Filing  
6/2/2016Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
4/22/2016Kevin M SlawinCTOSell55,000$11.43$628,650.00View SEC Filing  
1/4/2016Annemarie MoseleyCOOSell35,000$19.07$667,450.00View SEC Filing  
12/1/2015David M SpencerInsiderSell5,000$22.95$114,750.00View SEC Filing  
11/24/2015Alan A MussoCFOSell29,300$22.34$654,562.00View SEC Filing  
11/2/2015Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
10/1/2015Thomas J FarrellCEOSell2,500$14.58$36,450.00View SEC Filing  
9/11/2015David M SpencerInsiderSell5,000$19.00$95,000.00View SEC Filing  
9/1/2015Thomas J FarrellCEOSell2,500$16.78$41,950.00View SEC Filing  
7/15/2015Kevin M SlawinCTOSell6,000$20.00$120,000.00View SEC Filing  
6/16/2015David M SpencerInsiderSell20,000$22.96$459,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Latest Headlines for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Source:
DateHeadline
americanbankingnews.com logoFinancial Analysis: Bellicum Pharmaceuticals (BLCM) vs. The Competition
www.americanbankingnews.com - September 17 at 12:30 AM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (BLCM) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - September 14 at 7:16 PM
americanbankingnews.com logo Brokerages Expect Bellicum Pharmaceuticals, Inc. (BLCM) Will Post Quarterly Sales of $70,000.00
www.americanbankingnews.com - September 14 at 8:20 AM
americanbankingnews.com logo-$0.72 EPS Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - September 12 at 10:14 AM
americanbankingnews.com logoAnalyzing Bellicum Pharmaceuticals (BLCM) and its Competitors
www.americanbankingnews.com - September 12 at 4:26 AM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : September 11, 2017
finance.yahoo.com - September 11 at 5:15 PM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (BLCM) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 9 at 9:30 AM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BLCM) : September 6, 2017
finance.yahoo.com - September 5 at 11:13 PM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : September 1, 2017
finance.yahoo.com - September 1 at 4:51 PM
finance.yahoo.com logoBellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
finance.yahoo.com - August 30 at 5:52 PM
thestreet.com logoElliott Notches Win at Advisory Board, Monitors Progress with NRG - ICYMI - TheStreet.com
www.thestreet.com - August 29 at 9:59 PM
nasdaq.com logoBellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher - Nasdaq
www.nasdaq.com - August 29 at 4:58 PM
finance.yahoo.com logoBellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher
finance.yahoo.com - August 29 at 4:58 PM
americanbankingnews.com logoResearch Analysts Set Expectations for Bellicum Pharmaceuticals, Inc.'s FY2017 Earnings (BLCM)
www.americanbankingnews.com - August 28 at 3:18 AM
americanbankingnews.com logo$70,000.00 in Sales Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - August 26 at 1:30 AM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (BLCM) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - August 25 at 11:38 PM
americanbankingnews.com logo-$0.72 Earnings Per Share Expected for Bellicum Pharmaceuticals, Inc. (BLCM) This Quarter
www.americanbankingnews.com - August 24 at 10:24 PM
seekingalpha.com logoBellicum Offers A Promising Stock At Throwaway Prices
seekingalpha.com - August 17 at 5:58 PM
streetinsider.com logoBellicum Pharma (BLCM) Enters Cancer Research Grant Contract with CPRIT
www.streetinsider.com - August 16 at 3:29 AM
streetinsider.com logoBellicum Pharma (BLCM) Enters Cancer Research Grant Contract with CPRIT - StreetInsider.com
www.streetinsider.com - August 15 at 5:24 PM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 15 at 6:32 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Bellicum Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:BLCM)
www.americanbankingnews.com - August 11 at 9:48 AM
americanbankingnews.com logoSunTrust Banks Analysts Reduce Earnings Estimates for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
www.americanbankingnews.com - August 11 at 9:48 AM
finance.yahoo.com logoHouston pharma co. shakes up C-suite again
finance.yahoo.com - August 10 at 5:47 PM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (BLCM) Announces Earnings Results
www.americanbankingnews.com - August 9 at 10:04 PM
nasdaq.com logoBellicum Pharmaceuticals Reports Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - August 9 at 4:46 PM
benzinga.com logo22 Biggest Mid-Day Losers For Wednesday - Benzinga
www.benzinga.com - August 9 at 4:46 PM
finance.yahoo.com logoEdited Transcript of BLCM earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 4:46 PM
globenewswire.com logoBellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - August 8 at 4:20 PM
finance.yahoo.com logoInvestor Network: Bellicum Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 4:20 PM
finance.yahoo.com logoBellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 4:20 PM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Expected to Announce Quarterly Sales of $80,000.00
www.americanbankingnews.com - August 8 at 7:44 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Bellicum Pharmaceuticals, Inc. (BLCM) Will Announce Earnings of -$0.65 Per Share
www.americanbankingnews.com - August 6 at 12:22 PM
globenewswire.com logoBellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - August 4 at 4:06 AM
finance.yahoo.com logoBellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer
finance.yahoo.com - August 3 at 6:03 PM
feeds.benzinga.com logoBellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017
feeds.benzinga.com - August 1 at 7:23 AM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (BLCM) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 31 at 8:10 AM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : July 28, 2017
finance.yahoo.com - July 28 at 6:02 PM
finance.yahoo.com logoETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 3:54 PM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 21 at 9:18 AM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Expected to Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - July 19 at 3:02 PM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (BLCM) VP Sells $169,469.98 in Stock
www.americanbankingnews.com - July 17 at 7:15 PM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : July 14, 2017
finance.yahoo.com - July 14 at 11:34 PM
finance.yahoo.com logoETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 11:34 PM
americanbankingnews.com logoDavid M. Spencer Sells 10,000 Shares of Bellicum Pharmaceuticals, Inc. (BLCM) Stock
www.americanbankingnews.com - July 12 at 8:17 PM
americanbankingnews.com logoBellicum Pharmaceuticals, Inc. (BLCM) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - July 8 at 1:02 PM
seekingalpha.com logoBellicum Pharmaceuticals: A Story Of Hype And Hope - Seeking Alpha
seekingalpha.com - July 5 at 5:16 PM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BLCM) : July 3, 2017
finance.yahoo.com - July 3 at 4:41 PM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : June 30, 2017
finance.yahoo.com - June 30 at 4:36 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Rite Aid, Constellation, Acuity, Forestar, Bank stocks - Nasdaq
www.nasdaq.com - June 29 at 5:44 PM

Social

Chart

Bellicum Pharmaceuticals (BLCM) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff